DoseVault
Metabolic Compound

Dulaglutide

Weekly GLP-1 receptor agonist fused to an IgG4 Fc fragment; sold as Trulicity by Eli Lilly.

Scientific Overview

Dulaglutide (Trulicity, Eli Lilly, FDA-approved 2014) is a GLP-1 analog covalently linked to a human IgG4 Fc fragment, giving a half-life of ~5 days. The REWIND trial demonstrated CV benefit in T2DM with and without established CVD. Less weight loss than semaglutide/tirzepatide but strong cardio-metabolic profile.

Key Research Benefits

  • ✓Once-weekly dosing
  • ✓HbA1c reduction
  • ✓CV risk reduction (REWIND)

Potential Side Effects

⚠Nausea
⚠Diarrhea
⚠Injection-site reactions

Research Protocols

Common Dosages

T2DM

0.75 -> 4.5 mg
Weekly SC

“Titrate every 4 weeks”

Note: Dosages listed are common research protocols found in peer-reviewed literature and clinical trials. Individual results and requirements may vary significantly in a research context.

Dose Calculator

🧮 Peptide Reconstitution Calculator

mg

Total amount of peptide in the vial.

mL

Volume of water used to mix.

mcg

Draw to this mark

30 Units

or 0.30 mL on a U-100 syringe

Concentration:2.50 mg/mL
Peptide per Unit:25.00 mcg/unit
*Always double-check your calculations. This tool is for educational purposes only.

Explore Dulaglutide

Dulaglutide by goal

Read Dulaglutide's profile filtered through specific research goals.

Dulaglutide for Fat Loss

Molecular Profile

protein
GLP-1-IgG4 Fc fusion
275 AA Sequence

Quick Reference

Status
Research Compound
Category
Metabolic
Common Dosage
0.75 -> 4.5 mg
Weekly SC

Strictly for research purposes. Not for human consumption.

Related tools

Medical Disclaimer

Information provided on DoseVault is for educational and research purposes only. This website does not advocate for the human use of peptides. Peptides are currently sold as research chemicals and are not FDA-approved for human consumption. Always consult a licensed medical professional before considering any protocol.